David Scott Miller


AuthID: R-00K-250

Publicações Confirmadas: 317



61
TÍTULO: 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)
AUTORES: Colombo, N; Lorusso, D; Casado C Herráez; A.D Santin; Colomba, E; David Scott Miller ; Fujiwara, K; Pignata, S; Floquet, A; B.J Monk; Banerjee, S; R.T Penson; Kristeleit, R; Fabbro, M; Orlando, M; Mackay, H; Jensen, E; Dutta, L; Orlowski, R; Makker, V;
PUBLICAÇÃO: 2021, FONTE: Annals of Oncology, VOLUME: 32
INDEXADO EM: CrossRef: 18
NO MEU: ORCID | CIÊNCIAVITAE
62
TÍTULO: A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer  Full Text
AUTORES: Vicky Makker; Nicoletta Colombo; Antonio Casado Herráez; Alessandro Santin; Emeline Colomba; David Scott Miller ; Keiichi Fujiwara; Sandro Pignata; Sally Baron-Hay; Isabelle Ray-Coquard; Ronnie Shapira-Frommer; Kimio Ushijima; Jun Sakata; Kan Yonemori; Yong Man Kim; Eva Guerra; Ulus Sanli; Mary McCormack; Jie Huang; Alan Smith; Stephen Keefe; Lea Dutta; Robert Orlowski; Domenica Lorusso; ...Mais
PUBLICAÇÃO: 2021, FONTE: Gynecologic Oncology, VOLUME: 162
INDEXADO EM: CrossRef: 28
NO MEU: ORCID | CIÊNCIAVITAE
63
TÍTULO: Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis  Full Text
AUTORES: Kimberly Levinson; Anna L Beavis; Christopher Purdy; Anne F Rositch; Akila Viswanathan; Aaron H Wolfson; Michael G Kelly; Krishnansu S Tewari; Leah McNally; Saketh R Guntupalli; Omar Ragab; Yi Chun Lee; David Scott Miller ; Warner K Huh; Kelly J Wilkinson; Nicola M Spirtos; Linda Van Le; Yovanni Casablanca; Laura L Holman; Steven E Waggoner; Amanda N Fader; ...Mais
PUBLICAÇÃO: 2021, FONTE: Gynecologic Oncology, VOLUME: 162, NÚMERO: 3
INDEXADO EM: Scopus CrossRef: 32
NO MEU: ORCID | CIÊNCIAVITAE
64
TÍTULO: Corrigendum to “Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis” [Gynecologic Oncology 162 (2021) 532–538](S0090825821005114)(10.1016/j.ygyno.2021.06.017)  Full Text
AUTORES: Kimberly Levinson; Anna L Beavis; Christopher Purdy; Anne F Rositch; Akila Viswanathan; Aaron H Wolfson; Michael G Kelly; Krishnansu S Tewari; Leah McNally; Saketh R Guntupalli; Omar Ragab; Yi Chun Lee; David Scott Miller ; Warner K Huh; Kelly J Wilkinson; Nicola M Spirtos; Linda Van Le; Yovanni Casablanca; Laura L Holman; Steven E Waggoner; Amanda N Fader; ...Mais
PUBLICAÇÃO: 2021, FONTE: Gynecologic Oncology, VOLUME: 163, NÚMERO: 3
INDEXADO EM: Scopus CrossRef: 3
NO MEU: ORCID | CIÊNCIAVITAE
65
TÍTULO: Delayed time to surgery with hormonal treatment does not adversely impact outcomes in women with low-grade endometrioid endometrial cancer  Full Text
AUTORES: Sydney Oesch; Eugenia Kakadiaris; David Scott Miller ; Matthew Carlson; Jessica Lee; Salvatore Lococo; Jayanthi Lea;
PUBLICAÇÃO: 2021, FONTE: Gynecologic Oncology, VOLUME: 162
INDEXADO EM: CrossRef
NO MEU: ORCID | CIÊNCIAVITAE
66
TÍTULO: Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC).
AUTORES: Domenica Lorusso; Nicoletta Colombo; Antonio Casado Herraez; Alessandro Santin; Emeline Colomba; David Scott Miller ; Keiichi Fujiwara; Sandro Pignata; Sally E Baron-Hay; Isabelle Laure Ray-Coquard; Ronnie Shapira-Frommer; Yong Man Kim; Mary McCormack; Steven Bird; Vimalanand S Prabhu; Allison Martin Nguyen; Qi Zhao; Lea Dutta; Vicky Makker;
PUBLICAÇÃO: 2021, FONTE: Journal of Clinical Oncology, VOLUME: 39, NÚMERO: 15_suppl
INDEXADO EM: CrossRef: 9
NO MEU: ORCID | CIÊNCIAVITAE
67
TÍTULO: Is there a need for consultant team for bowel resection? An evaluation of surgical outcomes of bowel resection at time of ovarian cytoreductive surgery  Full Text
AUTORES: Terrence Wong; Matthew Carlson; Jayanthi Lea; Salvatore Lococo; David Scott Miller ; Jessica Lee;
PUBLICAÇÃO: 2021, FONTE: Gynecologic Oncology, VOLUME: 162
INDEXADO EM: CrossRef
NO MEU: ORCID | CIÊNCIAVITAE
68
TÍTULO: O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors
AUTORES: Makker, V; Colombo, N; Casado Herráez, A; Santin, A; Colomba, E; David Scott Miller ; Fujiwara, K; Pignata, S; Banerjee, S; Monk, B; Ushijima, K; Penson, R; Kristeleit, R; Fabbro, M; Orlando, M; Mackay, H; Ren, M; Orlowski, R; Dutta, L; Lorusso, D;
PUBLICAÇÃO: 2021, FONTE: Oral Abstracts
INDEXADO EM: CrossRef: 1
NO MEU: ORCID | CIÊNCIAVITAE
69
TÍTULO: O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775
AUTORES: Makker, V; Colombo, N; Casado Herráez, A; Santin, A; Colomba, E; David Scott Miller ; Fujiwara, K; Pignata, S; Baron-Hay, S; Ray-Coquard, I; Shapira, R; Ushijima, K; Sakata, J; Yonemori, K; YM Kim; EM Guerra; UA Sanli; Mccormack, M; Huang, J; AD Smith;
PUBLICAÇÃO: 2021, FONTE: Oral Abstracts
INDEXADO EM: CrossRef: 6
NO MEU: ORCID | CIÊNCIAVITAE
70
TÍTULO: Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance.
AUTORES: Ralynn Brann; Kevin Michael Kremer; Matthew Carlson; Salvatore LoCoco; Jayanthi Sivasothy Lea; David Scott Miller ; Jessica Lee;
PUBLICAÇÃO: 2021, FONTE: Journal of Clinical Oncology, VOLUME: 39, NÚMERO: 15_suppl
INDEXADO EM: CrossRef: 3
NO MEU: ORCID | CIÊNCIAVITAE
Página 7 de 32. Total de resultados: 317.

Um espaço para investigadores e suas Instituições

Links Úteis

Ajuda

© 2025 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service